Based on the Centessa Pharmaceuticals PLC ADR stock forecast from 6 analysts, the average analyst target price for Centessa Pharmaceuticals PLC ADR is USD 21.00 over the next 12 months. Centessa Pharmaceuticals PLC ADR’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Centessa Pharmaceuticals PLC ADR is Slightly Bearish, which is based on 3 positive signals and 5 negative signals. At the last closing, Centessa Pharmaceuticals PLC ADR’s stock price was USD 17.04. Centessa Pharmaceuticals PLC ADR’s stock price has changed by +6.50% over the past week, +12.48% over the past month and +160.55% over the last year.
No recent analyst target price found for Centessa Pharmaceuticals PLC ADR
No recent average analyst rating found for Centessa Pharmaceuticals PLC ADR
Company Overview Centessa Pharmaceuticals PLC ADR
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom. Read Less
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered O...Read More
Frequently Asked Questions About Centessa Pharmaceuticals PLC ADR (CNTA) Stock
Based on ratings from 6 analysts Centessa Pharmaceuticals PLC ADR's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 8 buy, sell and 1 hold ratings.
Unfortunately we do not have enough data on CNTA's stock to indicate if its a good dividend stock.
Based on targets from 6 analysts, the average taret price for CNTA is USD 21.00 over the next 12 months. The maximum analyst target price is USD 33 while the minimum anlayst target price is USD 11.
Unfortunately we do not have enough data on CNTA's stock to indicate if its overvalued.
The last closing price of CNTA's stock was USD 17.04.
The most recent market capitalization for CNTA is USD 2.11B.
Based on targets from 6 analysts, the average taret price for CNTA is projected at USD 21.00 over the next 12 months.
This means that CNTA's stock price may go up by +23.24% over the next 12 months.
We can't find any ETFs which contains Centessa Pharmaceuticals PLC ADR's stock.
As per our most recent records Centessa Pharmaceuticals PLC ADR has 76 Employees.
Centessa Pharmaceuticals PLC ADR's registered address is 1 Ashley Road, Altrincham, United Kingdom, WA14 2DT.
You can get more information about it from Centessa Pharmaceuticals PLC ADR's website at https://www.centessa.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Centessa Pharmaceuticals PLC ADR (CNTA) Stock
Based on ratings from 6 analysts Centessa Pharmaceuticals PLC ADR's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 8 buy, sell and 1 hold ratings.
Unfortunately we do not have enough data on CNTA's stock to indicate if its a good dividend stock.
Based on targets from 6 analysts, the average taret price for CNTA is USD 21.00 over the next 12 months. The maximum analyst target price is USD 33 while the minimum anlayst target price is USD 11.
Unfortunately we do not have enough data on CNTA's stock to indicate if its overvalued.
The last closing price of CNTA's stock was USD 17.04.
The most recent market capitalization for CNTA is USD 2.11B.
Based on targets from 6 analysts, the average taret price for CNTA is projected at USD 21.00 over the next 12 months.
This means that CNTA's stock price may go up by +23.24% over the next 12 months.
We can't find any ETFs which contains Centessa Pharmaceuticals PLC ADR's stock.
As per our most recent records Centessa Pharmaceuticals PLC ADR has 76 Employees.
Centessa Pharmaceuticals PLC ADR's registered address is 1 Ashley Road, Altrincham, United Kingdom, WA14 2DT.
You can get more information about it from Centessa Pharmaceuticals PLC ADR's website at https://www.centessa.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for CNTA !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
